ClinicalTrials.Veeva

Menu
E

Equity Medical LLC | New York, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Amlitelimab
Tirzepatide
Dupilumab
Ruxolitinib
Ixekizumab
Upadacitinib
LY2439821
Tildrakizumab
Lebrikizumab
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 16 total trials

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Active, not recruiting
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Active, not recruiting
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Topical corticosteroids

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Enrolling
Moderate to Severe Genital Psoriasis
Drug: Tildrakizumab 100 mg
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo
Locations recently updated

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Pr...

Active, not recruiting
Prurigo Nodularis
Drug: Ruxolitinib Cream 1.5%

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous i...

Enrolling
Lichen Simplex Chronicus
Drug: Placebo
Drug: Dupilumab

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Psoriasis
Overweight or Obesity
Drug: Tirzepatide

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic d...

Not yet enrolling
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Active, not recruiting
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling
Hidradenitis Suppurativa (HS)
Biological: Tibulizumab Dose B
Other: Placebo

Trial sponsors

Sanofi logo
AbbVie logo
Incyte logo
Lilly logo
Sun Pharma logo
Z

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems